Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?

"Competing interests MP receives research funding from various organisations including the MRC, NIHR and EU Commission. He has also received partnership funding for the MRC Clinical Pharmacology Training Scheme (cofunded by MRC and Roche, UCB, Eli Lilly and Novartis). He is member of the Innovative Health Initiative, ARDAT (www.ardat.org). RMT is now an employee of GSK; his work on this review started before this employment. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"Competing interests: MP receives research funding from various organisations including the MRC, NIHR and EU Commission. He has also received partnership funding for the MRC Clinical Pharmacology Training Scheme (cofunded by MRC and Roche, UCB, Eli Lilly and Novartis). He is member of the Innovative Health Initiative, ARDAT (www.ardat.org). RMT is now an employee of GSK; his work on this review started before this employment. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."